Navigation Links
Study Shows BSGI/MBI Contributes Significantly to Patient Management with Its Ability to Detect Breast Cancer in Difficult to Diagnose Patients
Date:12/14/2010

PITTSBURGH, Dec. 14, 2010 /PRNewswire/ -- Dr. Barbara Ward and others of Weinstein Imaging determined that Breast-Specific Gamma Imaging/Molecular Breast Imaging (BSGI/MBI) provides additional information when conventional imaging is indeterminate and greater confidence is required to improve diagnostic accuracy.  The data from the retrospective study demonstrated that BSGI contributed significantly to patient management by detecting cancer in 7 of the 73 patients (9%), and was presented last week at the San Antonio Breast Cancer Symposium.

BSGI/MBI is a molecular breast imaging technique that is used to identify early stage cancers by means of a high-resolution, small field-of-view gamma camera and a radiotracer. Cells with increased metabolic activity, such as rapidly dividing cancers, preferentially absorb this tracer and are viewed as dark spots on the BSGI image. BSGI is a diagnostic complement to mammography, and is especially helpful for patients with negative or indeterminate mammograms and an unresolved clinical concern such as indeterminate densities, new vague calcifications, bloody nipple discharge, focal breast pain or palpable masses; especially in those of elevated risk and patients with dense breast tissue.

The study included 73 patients with 79 regions of concern that were classified as indeterminate following mammography and ultrasound.  There were 7 biopsy proven malignant lesions and 72 benign findings on pathology or follow-up imaging.  BSGI was positive in 7 malignant and 21 benign lesions and negative in 51 benign lesions, yielding a sensitivity of 100% and specificity of 71%.  The study showed that BSGI/MBI is a useful complimentary tool in the diagnostic work up of patients when a diagnostic concern remains after negative or indeterminate conventional imaging.

About Dilon Diagnostics

Dilon Diagnostics, a brand of Dilon Technologies Inc., is bringing innovative medical imaging
'/>"/>

SOURCE Dilon Diagnostics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , August 3, 2015 ... by Persistence Market Research "Global Market Study on ... to Witness Highest Growth by 2022", the global physiotherapy ... Bn by the end of 2015 and is expected ... 2015 to 2022, to account for US$23.7 Bn by ...
(Date:8/3/2015)...  CytRx Corporation (NASDAQ: CYTR ), a biopharmaceutical ... financial results for the three months ended June 30, ... and upcoming milestones for its clinical development programs. ... productive for CytRx. Enrollment in our ongoing pivotal global ... sarcoma (STS) continues on track to be completed in ...
(Date:8/3/2015)... Aug. 3, 2015  Array BioPharma Inc. (NASDAQ: ... fourth quarter and full year of its fiscal ... Squarer, Chief Executive Officer of Array, noted, "Binimetinib and ... are on track for regulatory submissions in 2016. ... melanoma and BRAF-mutant colorectal cancer further validate the ...
Breaking Medicine Technology:Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 2Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 3Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 4CytRx Reports 2015 Second Quarter Financial Results 2CytRx Reports 2015 Second Quarter Financial Results 3CytRx Reports 2015 Second Quarter Financial Results 4CytRx Reports 2015 Second Quarter Financial Results 5CytRx Reports 2015 Second Quarter Financial Results 6CytRx Reports 2015 Second Quarter Financial Results 7CytRx Reports 2015 Second Quarter Financial Results 8CytRx Reports 2015 Second Quarter Financial Results 9CytRx Reports 2015 Second Quarter Financial Results 10CytRx Reports 2015 Second Quarter Financial Results 11CytRx Reports 2015 Second Quarter Financial Results 12CytRx Reports 2015 Second Quarter Financial Results 13CytRx Reports 2015 Second Quarter Financial Results 14Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12
... , , , , MUMBAI, India, Dec. ... IN, NSE: SUNPHARMA, BSE: 524715) today announced that based on ... (Pink Sheets: TAROF) annual general meeting, Taro,s minority shareholders sent ... continuing control of Taro. Shareholders voted decisively against the ...
... , DETROIT, Dec. 30 For the twelfth consecutive year, ... Christ, is campaigning to save lives during New Year,s Eve ... New Millennium, Health Alliance Plan (HAP) and the Wayne County ... celebrate the New Year without gunfire. The hope is ...
Cached Medicine Technology:Taro Shareholders to Levitt and Directors: Quit the Board 2Taro Shareholders to Levitt and Directors: Quit the Board 3Rev. Nick Hood, III Asks Southeast Michiganders Not to Use Guns During New Year's Eve Celebrations 2
(Date:8/3/2015)... ... August 03, 2015 , ... ... Appeals ruled in favor of the firm’s client Rebecca Hamsher, deciding that in ... Center must reimburse benefits for Hamsher’s residential treatment for bulimia, depression and other ...
(Date:8/3/2015)... ... 03, 2015 , ... A recent survey by the ... Hispanics believe people can positively affect their diabetes, few look beyond diet changes ... diet changes was important. Far fewer participants mentioned the need for exercise (30%), ...
(Date:8/3/2015)... ... 2015 , ... Novatus, Inc. today launched the largest and ... as announced the date of its next major release. , Version 6.0 introduces ... as well as enhancements to the customer experience. Users now enjoy a ...
(Date:8/3/2015)... Pass, OR (PRWEB) , ... August 03, 2015 ... ... Northeast California’s Modoc National Forest, to Ahjumawi Lava Springs, California’s northernmost and among ... of California’s largest untapped ground water aquifers, whose main outflow is at Ahjumawi ...
(Date:8/3/2015)... ... ... Illinois Health & Science (IHS) has completed the purchase of IBA Molecular North ... NA’s cyclotron sites and research and development facilities. , “We are excited ... a large manufacturing hub in Noblesville, Indiana,” said Ken Smithmier, President and CEO of ...
Breaking Medicine News(10 mins):Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:Novatus Unveils Milestone Software Release 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 4Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2
... for signed parental consent and health,history forms, Give Kids ... youth population they will see on February 1 - ... agencies and such. PLEASE DO NOT INDICATE TO THE ... COLUMBUS, Ohio, Jan. 24 In conjunction with,the Ohio ...
... at Melbournes Howard Florey Institute have discovered that ... dementia in the fatal genetic disease, Huntington,s disease. ... possibilities for other devastating and difficult to treat ... a key component. , The Floreys Dr ...
... symposium on gastrointestinal cancers , , THURSDAY, Jan. 24 (HealthDay ... a biomarker that could detect colorectal cancer in its ... accurate way than existing blood tests. , The marker, ... early- and late-stage disease, the researchers added. , The ...
... 24 ZYTO Corp. (Pink Sheets:,ZYTC) has announced the ... and Kami Howard as C.F.O., The internal appointments ... according to Dr. Vaughn R. Cook, company founder, president ... and handled the,financial responsibilities., Howard joined ZYTO in ...
... The following is a,statement by Blue Shield of California CEO ... advocate for universal coverage, I,m disappointed that we,did not clear ... Senate must,not make perfection the enemy of the good. This ... be., We have waited too long to make health ...
... Calif., Jan. 23 InterMune, Inc.,(Nasdaq: ITMN ) ... of InterMune, will present at the 2008 Wachovia Healthcare,Conference ... EST., To access a live audio webcast of ... to the investor relations page of InterMune,s,corporate website at ...
Cached Medicine News:Health News:Ohio Dental Volunteers to Give Over $1.1M in Free Care and Improve Oral Health of 18,000 Children in Need Through 6th Annual Give Kids A Smile! Day Ohio 2Health News:Ohio Dental Volunteers to Give Over $1.1M in Free Care and Improve Oral Health of 18,000 Children in Need Through 6th Annual Give Kids A Smile! Day Ohio 3Health News:Mental and physical exercise delays dementia in fatal genetic disease 2Health News:New Colon Cancer Test Might Spot Trouble Earlier 2Health News:New Colon Cancer Test Might Spot Trouble Earlier 3Health News:ZYTO Corp. Appoints New Chief Operations Officer and New Chief Financial Officer 2Health News:InterMune to Present at the 2008 Wachovia Healthcare Conference 2
Aplicare's disposable 1-ounce pouches are designed for individual application and are ideal for reducing waste. They are used in nursing homes, home healthcare settings, blood banks, laboratories, em...
... 10% Povidone Iodine USP, 1% available Iodine, ... prep, Povidone Iodine Gel helps to minimize ... patient, thus reducing the chance of patient ... a one step gel for venipuncture site ...
... Gel is a viscous antimicrobial that contains ... for broad-spectrum germicidal action. As a preoperative ... minimize the pooling of prepping solutions under ... patient burns. Povidone Iodine Topical Gel is ...
... Povidone Iodine Prep Solution is appropriate ... paint, wet soak or spray); disinfecting ... antiseptic treatment of lacerations and abrasions. ... anti-infective agent in hospital and office ...
Medicine Products: